2023
Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodesOutcomes on an inpatient oncology service after the introduction of hospitalist comanagement
Morris J, Rothberg BE, Prsic E, Parker N, Weber U, Gombos E, Kottarathara M, Billingsley K, Adelson K. Outcomes on an inpatient oncology service after the introduction of hospitalist comanagement. Journal Of Hospital Medicine 2023, 18: 391-397. PMID: 36891947, DOI: 10.1002/jhm.13071.Peer-Reviewed Original ResearchConceptsLength of stayInpatient oncology serviceSmilow Cancer HospitalSeverity of illnessOncology servicesOncologists' experiencesReadmission ratesEarly dischargeHospitalist comanagementAverage LOSTime of dischargeMean discharge timeEarly discharge ratesImpact of hospitalistsRace/ethnicityDischarge dispositionMultiple admissionsCancer HospitalMAIN OUTCOMEStudy durationPatient volumeCancer typesStudy periodHospitalistsOutcomes
2022
Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis
Sutton T, Wong L, Walker B, Dewey E, Eil R, Lopez C, Kardosh A, Chen E, Rocha F, Billingsley K, Mayo S. Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis. Surgery 2022, 173: 1314-1321. PMID: 36435651, DOI: 10.1016/j.surg.2022.10.019.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesPost-recurrence overall survivalRepeat hepatic resectionRecurrent colorectal liver metastasesHepatic resectionLiver metastasesSystemic treatmentOverall survivalIntrahepatic recurrenceOncologic outcomesSystemic therapyMedian post-recurrence overall survivalRetrospective single-institution cohort studySingle-institution cohort studyCurative-intent hepatectomyImproved oncologic outcomesPerioperative systemic therapyRelevant clinicopathologic variablesSignificant clinicopathologic differencesPropensity-matched analysisRole of resectionCox proportional hazardsLiver recurrencePerioperative chemotherapyCohort study
2020
Pandemic Recovery Using a COVID-Minimal Cancer Surgery Pathway
Boffa DJ, Judson BL, Billingsley KG, Galetta D, Fontanez P, Odermatt C, Lindner K, Mitchell MR, Henderson CM, Carafeno T, Pinto J, Wagner J, Ancuta M, Beley P, Turner AL, Banack T, Laurans MS, Johnson DC, Yoo P, Morton JM, Zurich H, Davis K, Ahuja N. Pandemic Recovery Using a COVID-Minimal Cancer Surgery Pathway. The Annals Of Thoracic Surgery 2020, 110: 718-724. PMID: 32417195, PMCID: PMC7227551, DOI: 10.1016/j.athoracsur.2020.05.003.Peer-Reviewed Original ResearchConceptsSurgery pathwayHospital-acquired COVID-19 infectionLarge academic medical centerCOVID-19 patientsCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 infectionPatient care pathwayAcademic medical centerDisease 2019 pandemicHealth care deliveryOnly surgerySurgery populationElective surgeryPatient survivalRisk of exposureProtection of patientsCare pathwayNosocomial infectionsMedical CenterCare deliverySurgical activityHospitalPatientsSurgeryMost hospitalsYttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt KK, Maynard E, Ahn J, Lhewa D, Farsad K. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent? CardioVascular And Interventional Radiology 2020, 43: 721-731. PMID: 32140840, DOI: 10.1007/s00270-020-02434-4.Peer-Reviewed Original ResearchConceptsC hepatocellular carcinomaChild-Pugh AAdvanced hepatocellular carcinomaOverall survivalHepatocellular carcinomaBCLC stage C hepatocellular carcinomaEastern Cooperative Oncology Group scoreBCLC-C hepatocellular carcinomasMultivariable Cox regression analysisChild-Pugh scoreMedian overall survivalChild-Pugh classKaplan-Meier methodCox regression analysisYttrium-90 RadioembolizationLog-rank testCautious patient selectionSignificant independent predictorsChild-PughHCV infectionResultsMean ageY90 radioembolizationAdditional malignanciesConsecutive patientsIndependent predictorsEffect of Time to Surgery of Colorectal Liver Metastases on Survival
Chen EY, Mayo SC, Sutton T, Kearney MR, Kardosh A, Vaccaro GM, Billingsley KG, Lopez CD. Effect of Time to Surgery of Colorectal Liver Metastases on Survival. Journal Of Gastrointestinal Cancer 2020, 52: 169-176. PMID: 32086781, PMCID: PMC7900034, DOI: 10.1007/s12029-020-00372-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColorectal NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRetrospective StudiesTime FactorsTime-to-TreatmentYoung AdultConceptsColorectal liver metastasesLong-term OSPostoperative overall survivalOverall survivalLonger TTSLiver metastasesWorse survivalDiagnosis of CLMLong-term survivorsResultsTwo hundred eightyRisk of recurrenceComprehensive cancer centerHigh disease burdenSpecific primary tumorsShorter TTSPerioperative chemotherapyPostoperative chemotherapyPerioperative treatmentResection marginsCancer CenterMetastasis characteristicsInstitutional databasePrimary tumorDisease burdenSimilar survival
2019
Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer? An Analysis of the National Cancer Database
Byrne RM, Gilbert EW, Dewey EN, Herzig DO, Lu KC, Billingsley KG, Deveney KE, Tsikitis VL. Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer? An Analysis of the National Cancer Database. Journal Of Surgical Research 2019, 238: 198-206. PMID: 30772678, DOI: 10.1016/j.jss.2019.01.039.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAppendiceal NeoplasmsChemotherapy, AdjuvantChemotherapy, Cancer, Regional PerfusionCytoreduction Surgical ProceduresDatabases, FactualFemaleHumansHyperthermia, InducedKaplan-Meier EstimateMaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesSex FactorsTreatment OutcomeUnited StatesConceptsPerioperative intraperitoneal chemotherapyAppendiceal cancerCytoreductive surgeryIntraperitoneal chemotherapyTreatment modalitiesNational Cancer Database dataMultivariate logistic regression analysisNational Cancer DatabasePatterns of careLow-grade tumorsNon-Hispanic ethnicityLogistic regression analysisMucinous malignanciesSystemic chemotherapyMultimodality treatmentClinical factorsImproved survivalPatient selectionMale sexKaplan-MeierPatient cohortCancer DatabaseWhite raceTreatment groupsChemotherapyHepatic resection of solitary HCC in the elderly: A unique disease in a growing population
Zarour LR, Billingsley KG, Walker BS, Enestvedt CK, Orloff SL, Maynard E, Mayo SC. Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population. The American Journal Of Surgery 2019, 217: 899-905. PMID: 30819401, DOI: 10.1016/j.amjsurg.2019.01.030.Peer-Reviewed Original ResearchConceptsSolitary hepatocellular carcinomaPrognostic nutritional indexHepatic resectionElderly patientsUnique diseaseLow prognostic nutritional indexMedian Child-Pugh scoreTumor size 5Child-Pugh scoreGrade III complicationsHalf of patientsRecurrence-free survivalSolitary HCCExtrahepatic recurrenceProspective databaseR0 resectionIntrahepatic recurrenceMajor hepatectomyMedian survivalOverall survivalViral hepatitisLow morbidityMedian ageClinicopathologic dataClinicopathologic differences
2018
Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson KT, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shasthri V, Iizuka S, Flynn P, Watson S, Korkola J, Courtneidge SA, Fischer JM, Jaboin J, Billingsley KG, Lopez CD, Burchard J, Gray J, Coussens LM, Sheppard BC, Wong MH. Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Advances 2018, 4: eaat7828. PMID: 30214939, PMCID: PMC6135550, DOI: 10.1126/sciadv.aat7828.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorCarcinoma, Pancreatic DuctalCell FusionCell Line, TumorCell SurvivalEpithelial CellsFemaleGreen Fluorescent ProteinsHumansHybrid CellsKaryotypingMacrophagesMaleMice, Inbred C57BLMice, TransgenicNeoplastic Cells, CirculatingPancreatic NeoplasmsTumor MicroenvironmentXenograft Model Antitumor AssaysConceptsNeoplastic cellsNumerous neoplastic cellsHuman cancer patientsUrgent medical needPotential therapeutic targetTumor-bearing miceLate-stage progressionHigh lethality rateFuels tumor progressionIdentification of biomarkersOverall survivalDisease stagePeripheral bloodCancer patientsTumor stagingMetastatic spreadNovel biomarkersTherapeutic targetBiologic mechanismsSolid tumorsMedical needMetastatic behaviorTumor progressionCancer highlightLethality rateEpirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas
Lu E, Perlewitz KS, Hayden JB, Hung AY, Doung YC, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, Ryan CW. Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas. Annals Of Surgical Oncology 2018, 25: 920-927. PMID: 29388122, DOI: 10.1245/s10434-018-6346-4.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasHigh-risk soft tissue sarcomasPhase II studyII studyPreoperative radiationTissue sarcomasHigh-grade soft tissue sarcomasHigh-risk STS patientsDistant disease-free survivalM2/dayExtensive institutional experienceLocal-regional failureDisease-free survivalRetrospective chart reviewDose-intense chemotherapyFavorable clinical outcomePercent of tumorsGy of radiationPostoperative cyclesTrimodality therapyPreoperative therapyWound complicationsChart reviewOverall survivalPathologic response
2017
Preoperative optimization for major hepatic resection
Walcott-Sapp S, Billingsley KG. Preoperative optimization for major hepatic resection. Langenbeck's Archives Of Surgery 2017, 403: 23-35. PMID: 29150719, DOI: 10.1007/s00423-017-1638-x.Peer-Reviewed Original ResearchConceptsMajor hepatic resectionHepatic resectionExercise capacityLiver diseaseMajor liver resectionUnderlying liver diseaseChronic liver diseasePrimary hepatobiliary malignanciesPathophysiology of changesPreoperative preparation programHepatectomy patientsPreoperative optimizationExercise toleranceMajor hepatectomyPostoperative complicationsLiver resectionMetastatic diseasePostoperative outcomesHepatobiliary malignanciesPreoperative evaluationExercise programExercise trainingFatty infiltrationHepatic steatosisMuscle strengthCetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713
Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713. Clinical Colorectal Cancer 2017, 17: e121-e125. PMID: 29233486, PMCID: PMC6598683, DOI: 10.1016/j.clcc.2017.10.008.Peer-Reviewed Original ResearchConceptsPathologic complete responseAdvanced rectal cancerNeoadjuvant chemoradiationRectal cancerInduction chemotherapyKRAS wild-type metastatic colorectal cancerWild-type metastatic colorectal cancerThree-year disease-free survivalLocally Advanced Rectal CancerMetastatic colorectal cancerDisease-free survivalPhase III trialsAdequate hematologicEligible patientsBowel obstructionSame regimenIII trialsPerformance statusRenal functionComplete responseImproved survivalClinical outcomesMicroscopic cancerRectal adenocarcinomaPatient eligibility
2015
Malignancy does not dictate the hypercoagulable state following liver resection
Gordon N, Riha G, Billingsley K, Schreiber M. Malignancy does not dictate the hypercoagulable state following liver resection. The American Journal Of Surgery 2015, 209: 870-874. PMID: 25805455, DOI: 10.1016/j.amjsurg.2014.12.022.Peer-Reviewed Original ResearchConceptsRelative hypercoagulable stateLiver resectionHypercoagulable stateMalignant diseaseTEG valuesMalignancy statusCause of hypercoagulabilityPostoperative coagulopathyCoagulation profileRetrospective reviewResectionNormal rangePatientsDiseaseSignificant differencesMalignancyMedian valueR timeStatusCoagulopathyHypercoagulabilityGroup
2014
Modern Technical Approaches in Resectional Hepatic Surgery
Michalski CW, Billingsley KG. Modern Technical Approaches in Resectional Hepatic Surgery. Surgical Oncology Clinics Of North America 2014, 24: 57-72. PMID: 25444469, DOI: 10.1016/j.soc.2014.09.007.Peer-Reviewed Original ResearchConceptsLiver resectionLiver surgeryPreoperative portal vein embolizationModern liver surgeryColorectal liver metastasesExtensive liver resectionPreoperative patient selectionPortal vein embolizationGroup of patientsBlood-sparing techniquesOverview of indicationsLiver metastasesPerioperative managementVein embolizationLow morbidityPatient selectionMultimodal treatmentHepatic surgeryResectionAdjunctive techniquesSurgeryModern technical approachesSafe performanceEmbolizationMorbidityChemoradiotherapy with a Radiation Boost for Anal Cancer Decreases the Risk for Salvage Abdominoperineal Resection: Analysis From the National Cancer Data Base
Geltzeiler C, Nabavizadeh N, Kim J, Lu K, Billingsley K, Thomas C, Herzig D, Tsikitis V. Chemoradiotherapy with a Radiation Boost for Anal Cancer Decreases the Risk for Salvage Abdominoperineal Resection: Analysis From the National Cancer Data Base. Annals Of Surgical Oncology 2014, 21: 3616-3620. PMID: 24943237, DOI: 10.1245/s10434-014-3849-5.Peer-Reviewed Original ResearchThe international normalized ratio overestimates coagulopathy in patients after major hepatectomy
Louis S, Barton J, Riha G, Orloff S, Sheppard B, Pommier R, Underwood S, Differding J, Schreiber M, Billingsley K. The international normalized ratio overestimates coagulopathy in patients after major hepatectomy. The American Journal Of Surgery 2014, 207: 723-727. PMID: 24791634, DOI: 10.1016/j.amjsurg.2013.12.021.Peer-Reviewed Original ResearchConceptsInternational normalized ratioMajor hepatectomyNormalized ratioPatient populationElevated international normalized ratioUse of thrombelastographyPostoperative day 1Postoperative time pointsHypercoagulable statePreoperative valuesDecreased incidenceProcoagulant factorsTEG measurementsCoagulation factorsDay 1ThrombelastographyHepatectomyFactor VIIISubsequent normalizationPatientsTime pointsHypocoagulabilityTherapyProtein C.
2013
Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy
Gur I, Diggs B, Wagner J, Vaccaro G, Lopez C, Sheppard B, Orloff S, Billingsley K. Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy. Journal Of Gastrointestinal Surgery 2013, 17: 2133-2142. PMID: 24091909, DOI: 10.1007/s11605-013-2295-1.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesPreoperative chemotherapyPerioperative chemotherapyOverall survivalLiver metastasesAdvanced ageResectable colorectal liver metastasesPreoperative portal vein embolizationShorter disease-free intervalAcademic oncology centerOutcomes Following ResectionThirty-day mortalityDisease-free intervalHigh-risk patientsPortal vein embolizationSubset of patientsPoor overall survivalLiver recurrenceSynchronous diseaseEleven patientsPostoperative complicationsRepeat resectionLiver resectionVein embolizationRetrospective reviewCoagulopathy after a liver resection: is it over diagnosed and over treated?
Barton J, Riha G, Differding J, Underwood S, Curren J, Sheppard B, Pommier R, Orloff S, Schreiber M, Billingsley K. Coagulopathy after a liver resection: is it over diagnosed and over treated? Hepato Pancreato Biliary 2013, 15: 865-871. PMID: 23458574, PMCID: PMC4503284, DOI: 10.1111/hpb.12051.Peer-Reviewed Original ResearchConceptsProthrombin time-international normalized ratioPost-operative time pointsLiver resectionPost-operative day 1Initiation of thromboprophylaxisLiver resection patientsNormal coagulation functionTime pointsPT-INR valuesTime of onsetProphylactic anticoagulationElective hepatectomyResection patientsPlasma transfusionHypercoagulable stateAnesthetic techniqueCoagulation functionNormalized ratioPlasma therapyPringle manoeuverRelative hypercoagulabilityFunctional assessmentDay 1ResectionThrombelastography
2012
Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer
Hessman C, Bubbers E, Billingsley K, Herzig D, Wong M. Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer. The American Journal Of Surgery 2012, 203: 649-653. PMID: 22405917, PMCID: PMC4285581, DOI: 10.1016/j.amjsurg.2012.01.003.Peer-Reviewed Original ResearchConceptsAldehyde dehydrogenase 1Cancer stem cellsClinical outcomesLoss of expressionCSC marker aldehyde dehydrogenase 1Advanced stage colorectal cancerMarker expressionMetastatic CRC samplesAmerican Joint CommitteeLate-stage diseaseColorectal cancer progressionEffective therapeutic targetNonmetastatic CRCMetastatic diseaseEarly CRCALDH1 expressionColorectal cancerCancer stageCRC tumorsCRC samplesTumors variesDisease prognosisNonmetastatic tumorsTherapeutic targetJoint Committee
2011
Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy
Massimino K, Kolbeck K, Enestvedt C, Orloff S, Billingsley K. Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy. Hepato Pancreato Biliary 2011, 14: 14-19. PMID: 22151446, PMCID: PMC3252986, DOI: 10.1111/j.1477-2574.2011.00402.x.Peer-Reviewed Original ResearchConceptsRight portal vein embolizationPortal vein embolizationFuture liver remnantShort-term outcomesFLR volumeVein embolizationPreoperative right portal vein embolizationMajor right hepatectomyPost-embolization complicationsPostoperative liver failureRecords of patientsResults of embolizationDegree of hypertrophyHypertrophy rateRight hepatectomyLiver resectionMost complicationsOperative complicationsOperative resectionPatient demographicsComplication rateLiver failureLiver insufficiencyOperative outcomesLiver remnant